Company: NOTV
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001628280-25-023370
Chunk: 103

Company: Inotiv, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part II, Item 1A
Chunk 103
---
 from areas using our offerings could negatively affect our business, revenue and financial results.

The following new risk factor is added to those disclosed under the heading "Risk Factors" appearing in Item 1A of Part I of the Annual Report on Form 10-K for the fiscal year ended September 30, 2024:

Regulatory changes in the pharmaceutical and biotechnology industries could reduce demand for our services and products.

Our business depends on helping clients navigate complex drug development regulations. While new or stricter regulations can increase demand for our services, changes such as relaxed regulatory requirements, expedited drug approvals, or rules that make our services less competitive could reduce the demand for our products and services. For example, the FDA Modernization Act 2.0, passed in December 2022, encourages the industry to explore alternatives to animal testing. A shift away from animal research could negatively impact our business, operations, or financial condition if we are unable to implement any approved alternatives, or if they do not deliver comparable financial results even if implemented.

ITEM 2 – UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Not applicable.

ITEM 3 – DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4 – MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5 – OTHER INFORMATION

Trading Arrangements

During the three months ended March 31, 2025, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any non-Rule 10b5-1 trading arrangement (as defined in the SEC’s rules), except as described in the table below:

Name & TitleDate AdoptedCharacter of Trading Arrangement (1)Aggregate Number of Common Shares to be Purchased or Sold Pursuant to Trading ArrangementDuration (2)R Matthew Neff, DirectorFebruary 13, 2025Rule 10b5-1 Trading Arrangement14,000 shares to be soldJanuary 1, 2026(1) Except as indicated by footnote, each trading arrangement marked as a “Rule 10b5-1 Trading Arrangement” is intended to satisfy the affirmative defense of Rule 10b5-1(c), as amended (the “Rule”).

(2)